Global Clinical Development TA Lead Nephrology and Orphan Disease Area will be
17th Clinical Trials Innovation Programme taking place on 02-03 March 2022 in Munich
Details of his Presentation are as follows
"Challenges and opportunities to conduct clinical studies in ANCA-Associated vasculitis, a rare and life-threatening disease, during and after Covid-19 pandemic"
- ANCA-Associated Vasculitis: disease overview (AAV)
- Patient’s clinical characteristics of GPA and MPA
- Novel potential therapeutic targets
- Patient’s perspectives regarding this condition
- Challenges and opportunities in AAV clinical setting during and after COVID-19 pandemic.
About Dr Domenico Merante
Dr Domenico Merante graduated in medicine in 1988 and became specialist of endocrinology and diabetes in 1993, both degrees were achieved at University of Pisa/Italy. Dr Merante has spent 26+ years in the pharmaceutical industry in Italy, UK, US and Switzerland dedicating his career to the clinical development of medicines to treat diabetes, diabetic complications (macular edema, painful diabetic neuropathy), severe hypertension, infectious diseases, hematology diseases (iron deficiency anemia and thrombocytopenia in chronic liver diseases), fibromyalgia and post-herpetic neuralgia. Dr Merante is currently Clinical Research Lead of Nephrology and Orphan Diseases at Vifor Pharma Headquarter in Zurich, Switzerland.
He previously worked at Sosei Heptares as VP of Clinical Development and before that at Shionogi UK as Head of Clinical Science in 2017 and 2018. Between 2007 and 2016 Dr Merante was Senior Director of Clinical Development at Daiichi Sankyo Development UK heading the European Frontiers/Opportunity Department. Dr Merante also covered clinical positions at Novo Nordisk in the UK and at GSK, Eli Lilly and Laboratori Guidotti in Italy. To date Dr Merante has produced 105 publications amongst full papers, abstracts or posters in reputed journals as either main or co-author and gave numerous presentations during National and International scientific conferences.
About Clinical Trials Innovation Programme
Clinical Trials Innovation Programme is an invitation-only, premium event bringing together a mix of clinical research professionals and service providers in one stimulating environment.Join us face to face to learn from the best in the drug development industry and have an opportunity to learn from their experiences.
Join us face to face to learn from the best in the drug development industry and have an opportunity to learn from their experiences. With an agenda covering the future of Clinical trials and drug development post COVID, Clinical Trials Innovation Programme 2022 will feature tailored sessions presented by the leading experts from across the globe.
We are bringing together the best in the industry to help you learn and grow, and accelerate your drug development journey. The experts will include thought leaders and visionaries from Danish Medicines Agency, Bayer Pharmaceuticals, AstraZeneca, The Janssen Pharmaceutical Companies of Johnson & Johnson, Travere Therapeutics, Biogen, Vifor Pharma, Medical Products Agency and much more.